http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103524409-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-233 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-233 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-14 |
| filingDate | 2013-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-09-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-09-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103524409-B |
| titleOfInvention | Quinolines and preparation method thereof and application |
| abstract | The present invention relates to medical art, particularly a class quinoline tyrosine kinase inhibitor, its preparation method and preparing the application in antitumor drug, this compounds has general structure (I):n compound disclosed by the invention has good tyrosine-kinase enzyme inhibition activity, particularly VEGFR2 and VEGFR3 inhibit activities, part preferred compound has also carried out the research of hepatomicrosome metabolic rate, absorption characteristic research in Caco-2 model and pharmacokinetics research. |
| priorityDate | 2013-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 123.